US 12,590,150 B2Granted

Antibody against Nectin-4 and application thereof

AssigneeMabwell (Shanghai) Bioscience Co., Ltd.

InventorsHongyuan Ren, Jian Zhu, Jian Lin, Lichun Wang, Xiaohong Xu, Xiaofang Deng, Jianjun Bi, Jin Wang, Jian Wu

Life of this patent

Estimating the term…

Abstract

Provided is an antibody molecule that binds to human Nectin-4 or a fragment thereof. The antibody is obtained by means of hybridoma screening and humanization techniques, and is used for the prevention or treatment of a cancer, and may be used as a clinical lead drug molecule.

Claims31

Dependent claims

An antibody molecule or fragment thereof, which comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising a combination of heavy and light chain CDRs selected from:

(1) CDR-H1 (GYTFTTY), CDR-H2 (YPGNVN), and CDR-H3 (GLYYFDY) shown in SEQ ID NOs:
35, 39, and 43;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRYT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 47, and 49;
(2) CDR-H1 (GYTFTTYYIH), CDR-H2 (WIYPGNVNTK), and CDR-H3 (GLYYFDY) shown in SEQ ID NOs:
36, 40, and 43;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRYT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 47, and 49;
(3) CDR-H1 (TYYIH), CDR-H2 (WIYPGNVNTKYNEKFKG), and CDR-H3 (GLYYFDY) shown in SEQ ID NOs:
37, 41, and 43;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRYT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 47, and 49;
(4) CDR-H1 (TTYYIH), CDR-H2 (WIGWIYPGNVNTK), and CDR-H3 (ARGLYYFD) shown in SEQ ID NOs:
38, 42, and 44;
and, CDR-L1 (SNDVAWY), CDR-L2 (LLIYYASNRY), and CDR-L3 (QQDYSSPY) shown in SEQ ID NOs:
46, 48, and 50;
(5) CDR-H1 (GFSLIDY), CDR-H2 (WGDGK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 55, and 59;
and, CDR-L1 (KSSQSLLNSYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
61, 63, and 65;
(6) CDR-H1 (GFSLIDYGVS), CDR-H2 (VIWGDGKIY), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
52, 56, and 59;
and, CDR-L1 (KSSQSLLNSYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
61, 63, and 65;
(7) CDR-H1 (DYGVS), CDR-H2 (VIWGDGKIYYNSVLKS), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
53, 57, and 59;
and, CDR-L1 (KSSQSLLNSYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
61, 63, and 65;
(8) CDR-H1 (IDYGVS), CDR-H2 (WLGVIWGDGKIY), and CDR-H3 (AKQGGLLFYAMD) shown in SEQ ID NOs:
54, 58, and 60;
and, CDR-L1 (LNSYSQKNYLAWY), CDR-L2 (LLIYFASTRE), and CDR-L3 (QQHYNTPF) shown in SEQ ID NOs:
62, 64, and 66;
(9) CDR-H1 (GFSLIDY), CDR-H2 (WGDGK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 55, and 59;
and, CDR-L1 (KSSQSLLNTYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
67, 63, and 65;
(10) CDR-H1 (GFSLIDY), CDR-H2 (WGDAK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 68, and 59;
and, CDR-L1 (KSSQSLLNTYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
67, 63, and 65;
(11) CDR-H1 (GFSLIDY), CDR-H2 (WGGGK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 69, and 59;
and, CDR-L1 (KSSQSLLNTYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
67, 63, and 65;
(12) CDR-H1 (GYTFTSY), CDR-H2 (YPGNAN), and CDR-H3 (SVYYFDY) shown in SEQ ID NOs:
70, 74, and 78;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRNT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 80, and 49;
(13) CDR-H1 (GYTFTSYYIH), CDR-H2 (WIYPGNANNK), and CDR-H3 (SVYYFDY) shown in SEQ ID NOs:
71, 75, and 78;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRNT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 80, and 49;
(14) CDR-H1 (SYYIH), CDR-H2 (WIYPGNANNKYNENFKG), and CDR-H3 (SVYYFDY) shown in SEQ ID NOs:
72, 76, and 78;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRNT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 80, and 49;
(15) CDR-H1 (TSYYIH), CDR-H2 (WIGWIYPGNANNK), and CDR-H3 (ARSVYYFD) shown in SEQ ID NOs:
73, 77, and 79;
and, CDR-L1 (SNDVAWY), CDR-L2 (LLIYYASNRN), and CDR-L3 (QQDYSSPY) shown in SEQ ID NOs:
46, 81, and 50;
(16) CDR-H1 (GYSFTDY), CDR-H2 (NPNNGN), and CDR-H3 (EDRYAFAY) shown in SEQ ID NOs:
82, 86, and 90;
and, CDR-L1 (RASQSVSTSSYTYMH), CDR-L2 (YASNLES), and CDR-L3 (QHTWEIPYT) shown in SEQ ID NOs:
92, 94, and 96;
(17) CDR-H1 (GYSFTDYYMH), CDR-H2 (RVNPNNGNTL), and CDR-H3 (EDRYAFAY) shown in SEQ ID NOs:
83, 87, and 90;
and, CDR-L1 (RASQSVSTSSYTYMH), CDR-L2 (YASNLES), and CDR-L3 (QHTWEIPYT) shown in SEQ ID NOs:
92, 94, and 96;
(18) CDR-H1 (DYYMH), CDR-H2 (RVNPNNGNTLYNQKFRG), and CDR-H3 (EDRYAFAY) shown in SEQ ID NOs:
84, 88, and 90;
and, CDR-L1 (RASQSVSTSSYTYMH), CDR-L2 (YASNLES), and CDR-L3 (QHTWEIPYT) shown in SEQ ID NOs:
92, 94, and 96;
and
(19) CDR-H1 (TDYYMH), CDR-H2 (WIGRVNPNNGNTL), and CDR-H3 (AREDRYAFA) shown in SEQ ID NOs:
85, 89, and 91;
and, CDR-L1 (STSSYTYMHWY), CDR-L2 (LLIKYASNLE), and CDR-L3 (QHTWEIPY) shown in SEQ ID NOs:
93, 95, and 97.

74 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/996,403Filed 21 Apr 2021
Priority: CN 202010320420.321 Apr 2020
Published: US 2023/0265183 A124 Aug 2023
Granted: 31 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification27 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/6817
The drug being a protein or peptide, e.g. transferrin or bleomycin: toxins
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…

Family

US 2023/0265183 A1Pre-grant publication · published 24 Aug 2023
US 12,590,150 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

(1) CDR-H1 (GYTFTTY), CDR-H2 (YPGNVN), and CDR-H3 (GLYYFDY) shown in SEQ ID NOs:
35, 39, and 43;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRYT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 47, and 49;
(2) CDR-H1 (GYTFTTYYIH), CDR-H2 (WIYPGNVNTK), and CDR-H3 (GLYYFDY) shown in SEQ ID NOs:
36, 40, and 43;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRYT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 47, and 49;
(3) CDR-H1 (TYYIH), CDR-H2 (WIYPGNVNTKYNEKFKG), and CDR-H3 (GLYYFDY) shown in SEQ ID NOs:
37, 41, and 43;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRYT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 47, and 49;
(4) CDR-H1 (TTYYIH), CDR-H2 (WIGWIYPGNVNTK), and CDR-H3 (ARGLYYFD) shown in SEQ ID NOs:
38, 42, and 44;
and, CDR-L1 (SNDVAWY), CDR-L2 (LLIYYASNRY), and CDR-L3 (QQDYSSPY) shown in SEQ ID NOs:
46, 48, and 50;
(5) CDR-H1 (GFSLIDY), CDR-H2 (WGDGK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 55, and 59;
and, CDR-L1 (KSSQSLLNSYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
61, 63, and 65;
(6) CDR-H1 (GFSLIDYGVS), CDR-H2 (VIWGDGKIY), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
52, 56, and 59;
and, CDR-L1 (KSSQSLLNSYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
61, 63, and 65;
(7) CDR-H1 (DYGVS), CDR-H2 (VIWGDGKIYYNSVLKS), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
53, 57, and 59;
and, CDR-L1 (KSSQSLLNSYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
61, 63, and 65;
(8) CDR-H1 (IDYGVS), CDR-H2 (WLGVIWGDGKIY), and CDR-H3 (AKQGGLLFYAMD) shown in SEQ ID NOs:
54, 58, and 60;
and, CDR-L1 (LNSYSQKNYLAWY), CDR-L2 (LLIYFASTRE), and CDR-L3 (QQHYNTPF) shown in SEQ ID NOs:
62, 64, and 66;
(9) CDR-H1 (GFSLIDY), CDR-H2 (WGDGK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 55, and 59;
and, CDR-L1 (KSSQSLLNTYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
67, 63, and 65;
(10) CDR-H1 (GFSLIDY), CDR-H2 (WGDAK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 68, and 59;
and, CDR-L1 (KSSQSLLNTYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
67, 63, and 65;
(11) CDR-H1 (GFSLIDY), CDR-H2 (WGGGK), and CDR-H3 (QGGLLFYAMDY) shown in SEQ ID NOs:
51, 69, and 59;
and, CDR-L1 (KSSQSLLNTYSQKNYLA), CDR-L2 (FASTRES), and CDR-L3 (QQHYNTPFT) shown in SEQ ID NOs:
67, 63, and 65;
(12) CDR-H1 (GYTFTSY), CDR-H2 (YPGNAN), and CDR-H3 (SVYYFDY) shown in SEQ ID NOs:
70, 74, and 78;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRNT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 80, and 49;
(13) CDR-H1 (GYTFTSYYIH), CDR-H2 (WIYPGNANNK), and CDR-H3 (SVYYFDY) shown in SEQ ID NOs:
71, 75, and 78;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRNT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 80, and 49;
(14) CDR-H1 (SYYIH), CDR-H2 (WIYPGNANNKYNENFKG), and CDR-H3 (SVYYFDY) shown in SEQ ID NOs:
72, 76, and 78;
and, CDR-L1 (KASQSVSNDVA), CDR-L2 (YASNRNT), and CDR-L3 (QQDYSSPYT) shown in SEQ ID NOs:
45, 80, and 49;
(15) CDR-H1 (TSYYIH), CDR-H2 (WIGWIYPGNANNK), and CDR-H3 (ARSVYYFD) shown in SEQ ID NOs:
73, 77, and 79;
and, CDR-L1 (SNDVAWY), CDR-L2 (LLIYYASNRN), and CDR-L3 (QQDYSSPY) shown in SEQ ID NOs:
46, 81, and 50;
(16) CDR-H1 (GYSFTDY), CDR-H2 (NPNNGN), and CDR-H3 (EDRYAFAY) shown in SEQ ID NOs:
82, 86, and 90;
and, CDR-L1 (RASQSVSTSSYTYMH), CDR-L2 (YASNLES), and CDR-L3 (QHTWEIPYT) shown in SEQ ID NOs:
92, 94, and 96;
(17) CDR-H1 (GYSFTDYYMH), CDR-H2 (RVNPNNGNTL), and CDR-H3 (EDRYAFAY) shown in SEQ ID NOs:
83, 87, and 90;
and, CDR-L1 (RASQSVSTSSYTYMH), CDR-L2 (YASNLES), and CDR-L3 (QHTWEIPYT) shown in SEQ ID NOs:
92, 94, and 96;
(18) CDR-H1 (DYYMH), CDR-H2 (RVNPNNGNTLYNQKFRG), and CDR-H3 (EDRYAFAY) shown in SEQ ID NOs:
84, 88, and 90;
and, CDR-L1 (RASQSVSTSSYTYMH), CDR-L2 (YASNLES), and CDR-L3 (QHTWEIPYT) shown in SEQ ID NOs:
92, 94, and 96;
and
(19) CDR-H1 (TDYYMH), CDR-H2 (WIGRVNPNNGNTL), and CDR-H3 (AREDRYAFA) shown in SEQ ID NOs:
85, 89, and 91;
and, CDR-L1 (STSSYTYMHWY), CDR-L2 (LLIKYASNLE), and CDR-L3 (QHTWEIPY) shown in SEQ ID NOs:
93, 95, and 97.

74 more elements

Facts

Application

17/996,403Filed 21 Apr 2021

Priority

CN 202010320420.321 Apr 2020

Published

US 2023/0265183 A124 Aug 2023

Granted

31 Mar 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification27 codes

C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 47/68031
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being an auristatin
A61K 47/6817
The drug being a protein or peptide, e.g. transferrin or bleomycin: toxins
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…